Brookline initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $9 price target TuHURA Biosciences is advancing innate immune agonists, checkpoint inhibitors, and antibody-drug conjugates to overcome checkpoint inhibitor resistance and to modulate tumor microenvironment, the analyst tells investors in a research note. The firm sees a favorable risk-reward as IFx-2.0 advances through the clinic, saying there is a significant unmet need for treatments to overcome CPI resistance in Merkel cell carcinoma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA:
- TuHURA Biosciences Approves Executive Salary Increases
- TuHURA announces FDA removed partial clinical hold on Phase 3 trial of IFx-2.0
- TuHURA Biosciences Secures $12.6M for Strategic Initiatives
- TuHURA Biosciences: Promising Oncology Advancements and Strategic Acquisitions Drive Buy Rating
- TuHURA Biosciences announces $12.5M private placement